Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment

  • Technology appraisal guidance
  • TA1001
  • Published: 
Download guidance (PDF)

2 Information about zanubrutinib

Marketing authorisation indication

2.1

Zanubrutinib (Brukinsa, BeiGene) is indicated for the treatment of 'adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy'.

Dosage in the marketing authorisation

Price

2.3

The list price for zanubrutinib is £4,928.65 per 120‑pack of 80‑mg capsules (excluding VAT; BNF online accessed May 2024).

2.4

The company has a commercial arrangement. This makes zanubrutinib available to the NHS with a discount. The size of the discount is commercial in confidence.